Pfizer (PFE) Non-Current Debt (2016 - 2025)
Pfizer (PFE) has disclosed Non-Current Debt for 17 consecutive years, with $61.6 billion as the latest value for Q4 2025.
- Quarterly Non-Current Debt rose 8.14% to $61.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.6 billion through Dec 2025, up 8.14% year-over-year, with the annual reading at $61.6 billion for FY2025, 8.14% up from the prior year.
- Non-Current Debt for Q4 2025 was $61.6 billion at Pfizer, up from $57.4 billion in the prior quarter.
- The five-year high for Non-Current Debt was $61.6 billion in Q4 2025, with the low at $31.7 billion in Q2 2023.
- Average Non-Current Debt over 5 years is $48.1 billion, with a median of $57.2 billion recorded in 2024.
- The sharpest move saw Non-Current Debt tumbled 30.03% in 2021, then skyrocketed 93.37% in 2024.
- Over 5 years, Non-Current Debt stood at $36.2 billion in 2021, then decreased by 9.15% to $32.9 billion in 2022, then surged by 87.14% to $61.5 billion in 2023, then fell by 7.37% to $57.0 billion in 2024, then grew by 8.14% to $61.6 billion in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods came in at $61.6 billion, $57.4 billion, and $57.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.